Pyrilutamide, also known as KX-826, is a high-affinity antagonist of the androgen receptor. It is currently undergoing phase II trials for male and female patients in the US and China.
The trial is assessing the change in non-vellus target area hair count after six months of treatment. The results should be available this year.
It is an anti-androgen
Pyrilutamide is a potent androgen antagonist that has completed phase-2 clinical trials for male pattern baldness. The drug, also known as KX-826, works by blocking testosterone and DHT from binding to the androgen receptor in hair follicles. It has less side effects than more commonly used treatments, such as finasteride and dutasteride.
Currently, Buy pyrilutamide is being researched as a treatment for androgenic alopecia in both the US and China. It has been shown to significantly increase hair density without the adverse side effects of oral 5-alpha reductase inhibitors such as decreased libido and erectile dysfunction.
Kintor Pharmaceuticals is a clinical stage company that develops innovative medicines for androgen receptor-related diseases with unmet medical needs. Their pipeline includes drugs such as Proxalutamide, KX-826, RG7203, GT20029, and Destorsertib. Their research is focused on identifying new small molecules with the potential to be developed as therapeutics for cancer and other diseases.
It is a topical anti-androgen
Pyrilutamide is a topical anti-androgen that works by binding to the androgen receptor in the hair follicle and blocking DHT. DHT is the main androgen that causes hair loss. It works differently than 5-alpha reductase inhibitors like finasteride and dutasteride. It does not reduce DHT levels, but it binds to the androgen receptor with equal affinity and blocks it from binding to testosterone.
It was developed by Kintor Pharmaceutical Limited, a clinical-stage company that discovers and develops novel small-molecule therapeutics. Its research and development operations focus on androgen receptor-related diseases that have unmet medical needs, such as androgenic alopecia and acne.
Buy pyrilutamide from MV Supplements (development code KX-826) is a potent and selective high-affinity silent antagonist of the androgen receptor. It is being developed by Suzhou Kintor Pharmaceuticals for the treatment of androgenic alopecia and acne in China and the US. It is also being investigated as a potential treatment for prostate cancer and other cancers.
It is a nonsteroidal anti-androgen
Pyrilutamide is a nonsteroidal anti-androgen that works by binding to and blocking the androgen receptor. It has been shown to have an excellent safety profile and a higher potency than finasteride or dutasteride. It also does not affect DHT levels, which may be beneficial for patients with FPHL or hirsutism. It is a similar drug to bicalutamide, which was used off-label for androgen-dependent hair loss but fell out of favor due to severe hepatic toxicity.
The drug is being developed by Kintor Pharmaceuticals, a company that focuses on androgen-receptor-related diseases with unmet needs, such as hair loss and acne. It is in phase II clinical trials for androgenetic alopecia and phase III trials for acne in China and the US. It is a high-affinity, silent antagonist that binds to the androgen receptor with an IC50 of 0.28 nM, which is comparable to the reference drug bicalutamide. PyriPure is a solution of pyrilutamide in a propylene glycol and ethanol vehicle. The raw material is >99% pure, and the product comes with a calibrated dropper for precise dosing.
It is a steroid
Pyrilutamide is a topical anti-androgen that has shown promising results in small clinical trials for male pattern hair loss. It is not yet available in the mainstream market, but it can be purchased online for research purposes. Its 0.5% solution consists of propylene glycol and ethanol. The raw material pyrilutamide (aka KX-826) is >99% pure and tested and confirmed by a third party. It comes with a calibrated dropper and should be stored in a cool place.
The drug is being developed by Kintor Pharmaceutical Ltd, which focuses on androgen receptor-related diseases with unmet medical needs. It is currently completing Phase II trials for androgenetic alopecia in China and the US. Its efficacy and safety are likely to be proven in a large multiregional, randomized placebo-controlled study that will be conducted this year. For more information about pyrilutamide, check out GlobalData’s Pyrilutamide LoA Report, which includes drug-specific PTSR and indication benchmarks based on 18 years of historical development data.